Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 2:32 AM
Ignite Modification Date: 2025-12-25 @ 2:32 AM
NCT ID: NCT02955134
Eligibility Criteria: Inclusion criteria 1. Patients diagnosed with chronic atrophic gastritis. 2. Patients whose pathological diagnosis was atrophy (reduction glands) of mild/moderate grade,with or without intestinal metaplasia, with or without mild/moderate dysplasia. 3. Aged between 40 to 65 years old, male or female. 4. Patients who agree to participate in the clinical study through informed consent. 5. Local residents ensuring regular treatment and follow-up. 6. Not taking aspirin, warfarin and other anticoagulants and those without coagulation disorders. Exclusion criteria 1. Autoimmune gastritis. 2. The combined gastric and duodenal ulcers, upper gastrointestinal bleeding. 3. Dysplasia of severe degree,or suspicious of gastric malignancy. 4. Serious comorbidities of heart, lung, liver, kidney or blood system (such as cardiac function above grade II, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal, creatinine (Cr) greater than the upper limit of normal and so on) or having a life-threatening illness . 5. Psychiatric disorders or a history of alcohol or drug abuse. 6. Pregnant or lactating women. 7. Allergic to the trial drug. 8. Patients judged inappropriate to participate in the trial by investigators. 9. Patients enrolled in another clinical trial last two months.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 40 Years
Maximum Age: 65 Years
Study: NCT02955134
Study Brief:
Protocol Section: NCT02955134